Bionike one-step tests were used to screen urine samples for amphetamines, rnethamphetamines, benzodiazepines, cannabinoids, methadone and opiates, and results were compared with those obtained using enzyme multiplied immunoassay technique d.a.u. assays. Taking into consideration different threshold levels and possible differences in cross-reactivities, there was good agreement between the methods. Results of Bionike tests correlated well with amphetamines, methadone and opiates detected in urine using gas chromatography-mass spectrometry. Bionike methods are rapid, simple to use, and relatively inexpensive for on-site testing of individual drugs or groups of drugs in urine.
Screening for drugs of abuse in urine is now widely used in the management of drug misusers, Analyses are usually performed by immunoassays, which are reliable, sensitive, simple to use and cost-effective. There has, however, been increasing interest in on-site testing by methods that can be used by non-laboratory staff outside a traditional laboratory environment. This form of near-patient testing has a number of advantages over laboratory-based testing, including the almost immediate availability of results; turnaround times for requests sent to a recognized diagnostic laboratory for drug screening may be several days.
A number of methods for on-site screening for drugs of abuse in urine are now available commercially. EZ-SCREEN tests (Environmental Diagnostics Inc, Burlington, NC, USA) are based on QUIK-CARDS coated with antibody to which is added urine, enzyme and substrate to produce a coloured product. The Abuscreen ONTRAK system (Roche Diagnostics, Welwyn Garden City, UK) is a qualitative latex agglutination immunological slide test. 1 Roche Diagnostics have also developed ONTRAK TESTCUP which is a multi-analyte immunochromatographic screening method.? The Triage Screening Cassette (Merck, Darmstadt, Germany) is a device based on competitive immunoassay that Correspondence; Dr D Simpson. 74 simultaneously detects seven or eight groups of abused drugs at concentrations above the cut-off levels recommended by the USA National Institute of Drug Abuse (NIDA)/Substance Abuse and Mental Health Services Administration (SAMSHA). 3 Evaluations of these tests have indicated that they are rapid, reliable and useful for on-site screening for suspected drug abuse and for checking for compliance. H However, George and Braithwaite? carried out a preliminary evaluation of five kits for on-site screening (manufacturers are not identified) and reported that all the kits were found to lack both sensitivity and specificity, and most kits gave an unacceptable proportion of false negative and false positive results.
Another method recently introduced into the UK is the Bionike A/Q One Step Tests (Bionike Inc, South San Francisco, CA, USA). These tests rely on competition for binding antibody between drugs coated on a membrane and drugs which may be present in the urine being tested. When a drug is present in the urine, it competes with membrane-bound drugs for the limited antibodies present as dye-antibody conjugates. When a sufficient amount of drug is present, it will prevent the binding of dye-antibody con: jugate to the membrane-bound drug. Therefore, a positive urine sample will not generate a colour band in the test region while the presence of a colour band in the test region indicates a negative result. Bionike tests are available commerically in the UK in the form of dipsticks and test cards; one stick or card is required for each analyte.
We have carried out an evaluation of six Bionike tests (amphetamine, methamphetamine, benzodiazepines, cannabinoids, methadone and opiates); cocaine metabolite and barbiturates were not included because positive tests are rarely encountered in the Lothians area. Tests were performed 'blind' and results compared with Syva enzyme multiplied immunoassay technique (EMIT) d.a.u. assays (Behring Diagnostics UK Ltd, Milton Keynes, UK) and gas chromatography-mass spectrometry (GC-MS).
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Patients' specimens Urine samples were obtained from suspected drug misusers and drug misusers on harm reduction therapy attending the Community Drug Problems Service, psychiatric clinics and general practice. Urines were also collected from drug users attending 'raves'. Rave samples were collected 6-12 h after ingestion of drugs. To minimize the risk of infection of staff by HIV and hepatitis Band C viruses, urines were heated to a temperature of 96°C for 30 min in a water bath prior to analysis." 
Bionike tests
The Bionike tests were carried out using dipsticks which consist of a test pad, a test area and an absorbing pad ( Fig. I) . For dip-stick tests, the end of the strip was placed into the sample until the urine was seen to move up through the test area. The strip was then placed in an upright position and coloured bands developed in the test area over a short period of time. Results were read between 1-8 min or 3-10 min depending on the test. A control band appears in all tests unless the test has failed. The presence of an additional coloured band in the test area indicates a negative result whilst the absence of this band indicates that the drug type for which the test is targeted is present in the urine at a concentration above the test threshold. Dip-stick tests for methadone were not available in the UK at the time of this study, and test cards in which strips are mounted on a card were used (Fig. 2) . The card contains a sample well into which two to three drops of Cannabinoids (threshold 50 IJ.g/L II-nor-!l-9-THe) II-nor-!l-9-THC-9-carboxylic acid 100 !l-9-tetrahydrocannabinol 500 Cannabinol 500
Methadone (threshold 300 IJ.g/L methadone) Information about threshold levels and crossreactivities of tests is given in the manufacturer's package inserts and cross-reaction information sheets and is summarized in Table 1 .
Amphetamines
Samples were analysed as previously described, 12 The limit for positive identification of the compounds tested was 100/lg/L.
Methadone
Methadone was identified in the basic drugs fraction of the Certify general extraction procedure. GC-MS detection was as described for amphetamines except that derivatization was not used and the mass range was 50--450amu. The limit for positive identification of methadone was 300/lg/L. The metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine was normally present in samples from patients taking methadone.
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Opiates
Morphine, codeine, dihydrocodeine and pholcodine were extracted by the Certify opiates extraction procedure, using nalorphine as internal standard. Trimethylsilyl derivatives were made by reacting the dried residue with BSTFA containing 1% TMCS (Pierce Chemical Co, Rockford, IL, USA), and were injected without further evaporation or dilution. Initial oven temperature was 120°C, held for I min, rising at 30 0 / m i n to 270°then at SO/min to 330°, held at 330°for 1min. Opiate derivatives were detected by selected ion monitoring, and quantitated with reference to a standard curve prepared by dilution of the pure drugs in human urine. A cut-off concentration of 50/lg/L was used for classification of samples as positive or negative for each opiate.
RESULTS
A comparison of the results of Bionike tests versus EMIT assays is given in Table 2 . A threshold level of 100 /lg/L is currently used in this laboratory for EMIT cannabinoids assays, but, in addition, a cut-off level of 50/lg/L was used to allow a more meaningful comparison. A cut-off of 50/lg/L is also recommended by SAMSHA, and 65 /lg/L is the current threshold for performance in the UK National External Quality Assurance Scheme (UKNEQAS) for drugs of abuse in urine. The percentage agreement between the Bionike and EMIT methods increased from 78% to 94% and the number of urines giving a positive result by Bionike and negative by EMIT was reduced from eight to two by using the 50 /lg/L level. The two samples which tested positive by the Bionike method had values of 40 and 44/lg/L by the EMIT method.
There was a 92% agreement between Bionike and EMIT methods for benzodiazepines, with no 'false positives' or 'false negatives'. The Bionike assay uses a threshold level of 300 /lg/L compared to 200/lg/L of oxazepam for EMIT but none of the samples tested had concentrations in the 200-300/lg/L range.
When results for the EMIT amphetamines polyclonal assay (cut-off 300 /lg/L for dand dlamphetamine, 650/lg/L for l-methamphetamine and 1000/lg/L for d-methamphetamine) were compared with those for the Bionike test for amphetamine and methamphetamine (cut-off levels both 1000 jl.g/L), the percentage agreement was 70% and 77%, respectively. The corresponding number of urines testing positive by EMIT and negative by Bionike for these tests were 13 (28%) and eight (17%), respectively. Table 3 gives a list of the amphetamines and related compounds detected in 29 urines by GC-MS compared with results for the Bionike and EMIT tests. For most samples there was good agreement between GC-MS and the other assays. As expected from cross-reactivity data, a urine containing only amphetamine tested positive by the Bionike amphetamine method but negative by the methamphetamine method. A 'false negative' result for 3,4-methylendioxymethamphetamine (MDMA) by the EMIT amphetamines assay could be explained by poor crossreactivity of the assay for MDMA. 13 A comparison of results for methadone by the Bionike and EMIT tests indicated 88% agreement. Of the five urines which tested MDMA,MDA  3  3  3  3  MDMA, MDEA  3  3  3  3  MDMA, MDEA, MDA  5 There was 91 % agreement between the Bionike and EMIT tests for opiates but two samples tested positive by the Bionike method and negative by EMIT (see Table 2 ). The concentrations obtained for these samples by EMIT were 21 and 48 Jlg/L and GC-MS analysis suggested the presence of dihydrocodeine at a concentration less than 50 Jlg/L. There was one false positive result by the EMIT method (Table  5) ; opiates were not detected by GC-MS and the urine tested negative by Bionike.
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DISCUSSION
In our experience the Bionike tests for the detection of drugs of abuse in urine are rapid, simple to use and reliable. The instructions provided with kits were clear and easy to follow.
Urines were collected in Universal containers and we found that dip-stick tests could be performed without the need to transfer the urine to the sample cup supplied by the manufacturer. Interpretation is subjective, but in most cases it was unambiguous although some results were classified as borderline. The manufacturer recommends that results should be read between 3-10 min but we found that interpretation of results was facilitated by leaving strips for 15-30 min; coloured bands appeared to be stable for at least several days. Appearance of a coloured band for negative tests and absence of a band for positive tests can be confusing initially. In general, however, there was good agreement between the Bionike and EMIT tests when differences in threshold levels and possible differences in cross-reactivities were taken into consideration. In most cases the Bionike test results compared well with GC-MS analyses.
Tests for methamphetamine were found to be reliable for the detection of MDMA but there was an indication that the amphetamine test may be less sensitive for the detection of 3,4methylenedioxyethamphetamine (MDEA). Failure to detect phenylpropanolamine could be a disadvantage because of an inability to detect possible use of Khat which is currently popular with young people attending raves.!"
The 9% of 'false positives' for the methadone assay (see Table 2 ) could be partly due to increased sensitivity and/or differences in crossreactivity relative to the EMIT assay as indicated in Table 4 . It is interesting to note that the Bionike package insert does not indicate if methadone metabolites are detected by this test, but the list of substances which do not cross-react does not include methadone metabolites and doxylamine (which can cross-react in the EMIT assay"),
The opiates test performed well by comparison with GC-MS and there was an indication that it was more reliable than EMIT assays. Unfortunately, the manufacturers do not give crossreactivities for dihydrocodeine and pholcodine and their metabolites.
In an evaluation carried out by Drial Consultants Inc, USA (personal communication), results of Bionike tests were compared with GC-MS. Sensitivity ('correlation of positive results between the two methods') was 100% for amphetamine, methamphetamine, cocaine and cannabinoids, and 98% for opiates. Specificity ('correlation of negative results between the two methods') ranged from 93% for the amphetamine test, which gave positives for some urines containing ephedrine, to 99% for cannabinoids. Good correlation was reported between the Bionike test and Syva EMIT II screening methods for amphetamines, methamphetamines, opiates and cannabinoids. This corroborates our findings where good correlation was obtained in all assays other than amphetamines-the reason being that the EMIT d.a.u. polyclonal assay was used in our study.
It is unlikely that the Bionike tests will be widely used for preliminary screening for a range of drugs in the laboratory or for near-patient monitoring because of the need for a separate strip for each analyte. The Triage system seems better suited and easier to use for the screening of a panel of analytes and has proved to be reliable in evaluations.r? it is, however, expensive (about £35 per sample for seven to eight assays). On the other hand, Bionike tests could prove valuable for obtaining rapid and reliable results for an individual test, e.g. checking for methadone at a methadone clinic. Rapid availability of results may also be particularly relevant in other situations where patient management may be affected such as patients in psychiatric hospitals suspected of using cannabis when outside the hospital and allowed further passes to leave the hospital if urine tests negative for cannabinoids. Bionike tests could also have a useful role in general practice and may be of value in some laboratories, e.g. using the methamphetamine test to check for MDMA when an EMIT amphetamines result is negative.
The Bionike tests are more expensive than the reagent costs for most laboratory preliminary screening procedures and confirmation by laboratory methods may be required, but at a cost of £2 per analyte for dip-sticks and £3 for cards (excluding delivery charges and VAT), the assays are relatively inexpensive for on-site testing.
Near-patient testing for drugs of abuse could lead to greater convenience to patients and improve clinical management if results are presented during consultation. However, it is essential to focus attention on several important aspects of this form of testing. Non-laboratory personnel should receive formal training in the use of tests and should be provided with information about compliance with safety legislation and policies, formal record keeping, sensitivity and specificity of tests, and the need for quality control and quality assurance.l'tP Confirmatory procedures using chromatographic techniques should be used to check unexpected results (positive or negative) and for differentiation of opiates and amphetamines.F In employment screening, and if there are legal implications, a strict chain of custody and confirmation of positives are mandatory.
